Brokerages expect CymaBay Therapeutics Inc (NASDAQ:CBAY) to announce earnings of ($0.16) per share for the current fiscal quarter, Zacks reports. Zero analysts have made estimates for CymaBay Therapeutics’ earnings. The highest EPS estimate is ($0.11) and the lowest is ($0.19). CymaBay Therapeutics reported earnings of ($0.38) per share in the same quarter last year, which would suggest a positive year over year growth rate of 57.9%. The firm is expected to announce its next quarterly earnings report on Tuesday, November 3rd.
According to Zacks, analysts expect that CymaBay Therapeutics will report full-year earnings of ($0.72) per share for the current fiscal year, with EPS estimates ranging from ($0.79) to ($0.58). For the next fiscal year, analysts forecast that the company will report earnings of ($1.02) per share, with EPS estimates ranging from ($1.34) to ($0.75). Zacks Investment Research’s EPS averages are a mean average based on a survey of sell-side research firms that follow CymaBay Therapeutics.
CymaBay Therapeutics (NASDAQ:CBAY) last issued its earnings results on Monday, August 10th. The biopharmaceutical company reported ($0.16) earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.23) by $0.07.
Several large investors have recently added to or reduced their stakes in CBAY. UBS Group AG lifted its holdings in CymaBay Therapeutics by 340.1% in the 1st quarter. UBS Group AG now owns 371,902 shares of the biopharmaceutical company’s stock worth $551,000 after purchasing an additional 287,393 shares in the last quarter. SG Americas Securities LLC purchased a new position in shares of CymaBay Therapeutics in the first quarter worth $40,000. State Street Corp boosted its position in shares of CymaBay Therapeutics by 0.8% during the first quarter. State Street Corp now owns 1,421,566 shares of the biopharmaceutical company’s stock worth $2,104,000 after acquiring an additional 11,652 shares during the last quarter. Acadian Asset Management LLC grew its stake in CymaBay Therapeutics by 47.9% during the first quarter. Acadian Asset Management LLC now owns 611,297 shares of the biopharmaceutical company’s stock valued at $906,000 after acquiring an additional 198,002 shares in the last quarter. Finally, JPMorgan Chase & Co. increased its holdings in CymaBay Therapeutics by 3,382.3% in the 1st quarter. JPMorgan Chase & Co. now owns 786,408 shares of the biopharmaceutical company’s stock valued at $1,164,000 after acquiring an additional 763,825 shares during the last quarter. Hedge funds and other institutional investors own 85.99% of the company’s stock.
Shares of NASDAQ CBAY traded up $0.15 during midday trading on Wednesday, hitting $6.64. 1,831,434 shares of the stock traded hands, compared to its average volume of 2,903,799. The firm has a market capitalization of $457.41 million, a P/E ratio of -5.77 and a beta of 1.72. CymaBay Therapeutics has a one year low of $1.21 and a one year high of $7.09. The company has a debt-to-equity ratio of 0.01, a quick ratio of 18.37 and a current ratio of 18.37. The firm has a 50-day moving average of $5.79 and a two-hundred day moving average of $3.49.
About CymaBay Therapeutics
CymaBay Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on developing and providing therapies to treat liver and other chronic diseases. Its lead product candidate is seladelpar, a selective agonist of peroxisome proliferator-activated receptor delta, which has completed Phase II clinical study for the treatment of primary biliary cholangitis, as well as patients with nonalcoholic steatohepatitis.
Featured Article: How a Strangle Strategy is different from a Straddle Strategy
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for CymaBay Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CymaBay Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.